Machina Capital S.A.S. raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,704 shares of the company’s stock after buying an additional 213 shares during the quarter. Machina Capital S.A.S.’s holdings in Johnson & Johnson were worth $419,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in JNJ. Veracity Capital LLC increased its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares in the last quarter. LCM Capital Management Inc grew its stake in shares of Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the period. Arbor Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the period. Sierra Capital LLC grew its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the period. Finally, Retirement Planning Group grew its stake in shares of Johnson & Johnson by 1.8% during the 4th quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 67.57% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the subject of a number of recent research reports. Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target for the company. Raymond James cut their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Morgan Stanley boosted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $169.77.
Johnson & Johnson Stock Down 0.5 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.67 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
